PDCD1 and hepatocellular carcinoma: Despite the remarkable improvement in clinical benefit, PD-1 or PD-L1 blockades so far still benefit only a minority of patients with HCC and the durable response rate to anti-PD-1 therapy remains relatively low, approximately 15%–20%, in patients with HCC (5, 10).